Guardant Health Q4 Adj EPS $(0.64) Beats $(0.87) Estimate, Sales $155.05M Beat $149.57M Estimate
Portfolio Pulse from Benzinga Newsdesk
Guardant Health (NASDAQ:GH) reported Q4 adjusted EPS of $(0.64), surpassing the $(0.87) estimate, and sales of $155.05M, exceeding the $149.57M estimate. This represents a 45.3% decrease in losses per share and a 22.19% increase in sales compared to the same period last year.
February 22, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health reported a significant beat on both EPS and sales estimates for Q4, showing substantial improvement over the previous year.
The positive earnings report from Guardant Health, with better-than-expected EPS and sales figures, indicates strong performance and operational efficiency improvements over the past year. This is likely to instill investor confidence and could lead to a short-term uptick in the stock price, given the substantial beat on both key financial metrics.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100